Healthcare Private Placement and M&A Transactions Review Week Ending Jan 26, 2025

Tune Therapeutics: The company raised $182.4 million of Series B venture funding in a deal led by Hevolution Foundation, Regeneron Ventures and Yosemite on January 23, 2025, putting the company’s pre-money valuation at $157.4 million. RV Invest, Duke Capital Partners, Biovision Ventures, WRF Capital and Pappas Capital also participated in the round. The company is a developer of an epigenetic programming platform designed to create new pathways for the treatment of disease.

Rad AI: The company raised $60 million of Series C venture funding in a deal led by Transformation Capital on January 21, 2025, putting the company’s pre-money valuation at $525 million. The company is a developer of a generative AI radiology platform designed to save time, and improve patient care.

Eleos Health: The company raised $60 million of Series C funding in a deal led by Greenfield Partners on January 22, 2025. Eight Roads, Centerstone, lool ventures, Union Tech Ventures, F-Prime Capital, Menlo Ventures, ION Asset Management and the Michael & Susan Dell Foundation also participated in the round. The company is a developer of an AI platform that streamlines documentation, simplifies compliance, and surfaces deep care insights to drive better client outcomes.

Lindus Health: The company raised $55 million of Series B venture funding in a deal led by Balderton Capital on January 22, 2025. Creandum, Visionaries Club, Firstminute Capital, and Seedcamp also participated in the round. The company is an operator of a full-service, comprehensive contract research organization intended to deliver end-to-end clinical trials for health and biotech companies.

Field Medical: The company raised $26.9 million of venture funding from undisclosed investors on January 21, 2025. The company is an operator of a medical device business focused on developing advanced pulsed field ablation (PFA) technology for cardiac ablation procedures.

Lifespin: The company is in the process of raising EUR 10 million of venture funding from undisclosed investors as of January 24, 2025, putting the company’s pre-money valuation at EUR 32 million. The company is an operator of a deep data business developing a proprietary AI-based health testing platform to measure quantitative metabolic data in patient samples.

Syntis Bio: The company raised $6.3 million of venture funding from undisclosed investors on January 24, 2025. The company is a developer of late-stage preclinical drugs designed for oral therapy for obesity, diabetes, and rare diseases.

Springbok Analytics: The company raised $5 million of Series A venture funding in a deal led by Transition Equity Partners on January 24, 2025. National Basketball Association, Alumni Ventures, Cartan Capital, Boston Global Group and other undisclosed investors also participated in the round. The company is a developer of a muscle analytics platform designed to transform magnetic resonance images into holistic, interactive three-dimensional twins of an athlete’s exact musculature.

Akina: The company raised EUR 3 million of venture funding from Freigeist on January 24, 2025. The company is a developer of artificial intelligence healthcare software designed to enable connected physiotherapy at home.

Sen-Jam Pharmaceutical: The company raised an undisclosed amount of venture funding in a deal led by 5 Horizons Capital on January 22, 2025. The company is an operator of a biotech business intended to treat inflammation and metabolic disorders.

Nimble Therapeutics / AbbVie: The company was acquired by AbbVie for $200 million on January 23, 2025. The company is a developer of oral peptide therapeutics intended for immune-mediated diseases.

Orb Health / Respiri: The company was acquired by Respiri for $8.3 million on January 21, 2025. The company is a developer of a collaborative care platform designed to offer scalable chronic care management.

CANDOR Bioscience / Medix Biochemica: The company was acquired by Medix Biochemica, via its financial sponsors Coller Capital, DevCo Partners, Elo Mutual Pension Insurance, Security Trading and Valtion Eläkerahasto through an LBO on January 22, 2025 for an undisclosed amount. The company specializes in solutions for immunodiagnostics and immunoassay development.  CANDOR solutions include Human anti-mouse antibody (HAMA) and interference blockers, stabilizers, and surface blockers.

GPC Bio USA / Solar Biotech: The company was acquired by Solar Biotech for an undisclosed amount on January 22, 2025. The company is a developer of custom-designed bioreactors intended for mammalian cell culture applications.

Meddbase / Cority: The company was acquired by Cority, via its financial sponsors Thoma Bravo, Norwest Venture Partners, Ares Capital and Teralys Capital, through an LBO on January 23, 2025 for an undisclosed amount. The company is a developer of an EHR solution for healthcare professionals seeking a secure practice management and patient record system.

Surgery Hero / Sword Health: The company was acquired by Sword Health for an undisclosed amount on January 23, 2025. The company is an operator of a digital care platform intended for surgery preparation, perioperative care, and recovery.

Tinnitracks / Infectopharm Arzneimittel Und Consilium: The company was acquired by Infectopharm Arzneimittel Und Consilium for an undisclosed amount on January 23, 2025. The company is an operator of a medical technology business that offers tinnitus therapy through filtered music.

TRU Biologix / Emergent Medical Technologies: The company was acquired by Emergent Medical Technologies for an undisclosed amount on January 22, 2025. The company is a developer of regenerative medicine intended to restore cells and tissues.

Yoomi / Raintree Systems: The company was acquired by Raintree Systems, via its financial sponsor Serent Capital, through an LBO on January 24, 2025 for an undisclosed amount. The company is an operator of an AI-based platform intended to provide physical therapy services.